QuantaMatrix

QuantaMatrix Financial Leverage

The Financial Leverage (Equity Multiplier) of QuantaMatrix (317690.KQ) as of Oct 27, 2026 is 1.32. In the previous year, Financial Leverage (Equity Multiplier) was 4.11 — a change of -67.95% (lower).

Financial Leverage

1.32

YoY

-67.95%

Last updated:

Financial Leverage (Equity Multiplier) of QuantaMatrix is 2025 1.32 . Financial Leverage (Equity Multiplier) of QuantaMatrix was 2024 4.11 . It decreases by -67.95% lower compared to the previous year.

The QuantaMatrix Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
-0.79 KRW
Jan 1, 2019
1.13 KRW
Jan 1, 2020
1.07 KRW
Jan 1, 2021
1.09 KRW
Jan 1, 2022
1.14 KRW
Jan 1, 2023
1.25 KRW
Jan 1, 2024
4.11 KRW
Jan 1, 2025
1.32 KRW
The QuantaMatrix Financial Leverage history
YEARFinancial LeverageYoY
1.32-67.95%
4.11+228.39%
1.25+9.40%
1.14+4.70%
1.09+1.84%
1.07-5.40%
1.13-243.70%
-0.79+53.09%
-0.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuantaMatrix stock

Financial Leverage (Equity Multiplier) of QuantaMatrix is 1.32 in 2025.

Financial Leverage (Equity Multiplier) of QuantaMatrix changed from 4.11 to 1.32, representing a -67.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s QuantaMatrix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — QuantaMatrix

All Key Metrics — QuantaMatrix